30 Juin Un partenaire de CellProthera, le Pr David SMADJA, a présenté les résultats de phase 1/2b sur la qualité de vie obtenus avec la thérapie cellulaire ProtheraCytes® lors du congrès ISTH
Mulhouse, France, June 22, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, announces the presentation today of new clinical data by collaborators from Université Paris Cité, demonstrating improvements in health-related quality of life (HRQoL) for patients receiving ProtheraCytes® in a Phase 1/2b trial. ProtheraCytes® are CellProthera’s autologous CD34+ stem cell therapy, currently moving toward Phase 3 testing in patients following acute myocardial infarction. The data was presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2025 by David Smadja, team leader in endotheliopathy and hemostasis disorders at the Paris Cardiovascular Research Center (PARCC), Université Paris Cité.
Mortality and hospitalization for heart failure for patient’s post-heart attack has remained a challenge due to dangerous remodeling that can occur after AMI. The new presentation builds on the clinical evidence from the recently completed Phase 1/2b EXCELLENT trial, which demonstrated positive safety and efficacy for ProtheraCytes in these patients, including improvement of reverse remodeling. Prof. Smadja’s team examined quality of life measures for patients enrolled in the EXCELLENT trial such as physical health, pain, and vitality. The poster presentation will show that patients’ physical and social functioning were significantly improved for patients who received ProtheraCytes®.
Additionally, CellProthera and Prof. Smadja are continuing with a preclinical collaboration to study and characterize the properties of ProtheraCytes®. This will lead to better understanding of the cells’ mechanism of action and therapeutic potential, with important implications for CellProthera’s future development programs, including the forthcoming Phase 3 trial of ProtheraCytes®.
“Patients who have a serious heart attack face both short-term and long-term danger, » said Prof. Smadja. “ProtheraCytes® represent an opportunity to leverage and amplify patients’ natural regenerative mechanisms to improve their recovery and quality of life. I am encouraged by working with the CellProthera team that has already demonstrated the value and potential of this therapeutic approach.”
“Professor Smadja is a globally renowned expert in vascular biology and regenerative medicine, and we are fortunate to benefit from his expertise as we work to increase our knowledge of the mechanisms of action of our CD34+ cell therapy,” said Matthieu de Kalbermatten, CEO of CellProthera.
Poster presentation:
- PB0037 – ProtheraCytes are Expanded CD34+ Enhancing Quality of Life after injection in Myocardial Infarction
- Time: Sunday, Jun 22, 2025 1:45 PM – 2:45 PM EDT
- Location: Exhibition Hall D & E, Walter E. Washington Convention Center
- Session Code: 13159
About CellProthera
CellProthera is a regenerative cell therapy developer specializing in ischemic diseases, with a leading program in myocardial infarction. CellProthera has developed a unique GMP-compliant cell expansion process as well as proprietary automation technology for in vitro production of a large quantity of purified, expanded CD34+ cells. Its lead therapy ProtheraCytes®, is an autologous cell therapy targeted to regenerate various damaged tissues, including cardiac tissue. ProtheraCytes is registered as an Advanced Therapy Medicinal Product – ATMP – by the European Medicines Agency (EMA). CellProthera’s proprietary technology platform comprises an automated expansion device called StemXpand® and its single use kit StemPack®. CellProthera is headquartered in Mulhouse, France.